Phio Pharmaceuticals to present INTASYL platform at NIBA conference

Phio Pharmaceuticals will present at the National Investment Banking Association’s 153rd Conference on Oct. 7 in Fort Lauderdale, Florida, with CEO Robert Bitterman outlining the company’s INTASYL siRNA platform and an update on lead program PH-762 in cutaneous squamous cell carcinoma. The appearance gives Phio a venue to pitch its clinical strategy and meet investors one-on-one.

Why it matters: - Phio Pharmaceuticals is using the NIBA conference to pitch its cancer drug platform to investors at a time when the company is advancing a clinical-stage skin cancer program. - The presentation will focus on PH-762, which Phio positions as a potential non-surgical treatment for cutaneous squamous cell carcinoma and other skin cancers. - The event also gives Phio a direct forum to discuss its investment thesis with micro-cap and small-cap investors.

What happened: - Phio Pharmaceuticals accepted an invitation to present at the National Investment Banking Association’s 153rd Conference on Oct. 6-7, 2026, in Fort Lauderdale, Florida. - Robert Bitterman, Phio’s president and CEO, will present on Oct. 7 at 12:40 p.m. EDT at The Westin Fort Lauderdale Beach Resort. - Bitterman and Lisa Carson, Phio’s CFO, will participate in the event and take one-on-one meetings with investors. - The presentation will cover Phio’s INTASYL siRNA therapeutic platform, its delivery approach and the company’s strategic direction. - The update will also include PH-762, Phio’s lead clinical-stage program in cutaneous squamous cell carcinoma.

The details: - Phio describes INTASYL as a proprietary siRNA gene-silencing platform designed to enhance immune-cell function in solid tumors. - PH-762 silences the PD-1 gene, which is implicated in several forms of skin cancer. - The Phase 1b trial for PH-762, identified as NCT# 06014086, evaluated the program in cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma. - Phio says PH-762 is designed as a non-surgical option for skin cancers. - NIBA is a nonprofit that has served the micro-cap and small-cap investment community for almost 50 years. - Phio is a B2i Digital Featured Company, with an online profile available at the company profile. - NIBA’s conference website is available at the conference website.

Between the lines: - The conference presentation is as much a capital-markets event as a scientific update, giving Phio a chance to frame its technology for investors who follow early-stage biotech. - Phio’s messaging centers on a differentiated delivery approach and a strong safety profile, which are key claims for any oncology platform trying to stand out in a crowded field. - The company’s emphasis on immune-cell enhancement suggests it is positioning INTASYL as a platform technology, not just a single drug asset.

What's next: - Phio’s next public milestone is the Oct. 7 presentation in Fort Lauderdale. - The company said it plans to discuss its next phase of development for PH-762, including future FDA interactions and clinical trial design. - Phio also said activities supporting the next phase of PH-762 development are expected to be completed in the first quarter of 2027. - The company cautioned that forward-looking plans are subject to regulatory, clinical and financing risks.